Aytu BioPharma (AYTU) 10-Q 11 Feb 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2020	Feb. 01, 2021
Document Information [Line Items]
Entity Registrant Name	AYTU BIOSCIENCE, INC
Entity Central Index Key	0001385818
Trading Symbol	aytu
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		17,882,893
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Dec. 31, 2020	Jun. 30, 2020
Current assets
Cash and cash equivalents	$ 62,032,642	$ 48,081,715
Restricted cash	251,964	251,592
Accounts receivable, net	7,001,068	5,175,924
Inventory, net	6,571,254	9,999,441
Prepaid expenses and other	6,081,766	5,715,089
Other current assets	10,598,771	5,742,011
Total current assets	92,537,465	74,965,772
Fixed assets, net	89,663	258,516
Right-of-use asset	310,479	634,093
Finite-lived intangible assets, net	45,699,000	48,855,000
Deposits	16,023	32,981
Goodwill	28,090,407	28,090,407
Total long-term assets	74,204,631	77,870,558
Total assets	166,742,096	152,836,330
Current liabilities
Accounts payable and other	7,157,208	11,824,560
Accrued liabilities	8,877,715	7,849,855
Accrued compensation	2,540,353	3,117,177
Debt	41,318	982,076
Contract liability	475,680	339,336
Current lease liability	100,263	300,426
Current portion of fixed payment arrangements	1,937,476	2,340,166
Current portion of CVR liabilities	977,475	839,734
Current portion of contingent consideration	3,705,931	713,251
Total current liabilities	25,813,419	28,306,581
Long-term contingent consideration, net of current portion	12,573,916	12,874,351
Long-term lease liability, net of current portion	211,056	725,374
Long-term fixed payment arrangements, net of current portion	9,945,554	11,171,491
Long-term CVR liabilities, net of current portion	5,494,112	4,731,866
Other long-term liabilities	11,371	11,371
Total liabilities	54,049,428	57,821,034
Commitments and contingencies (Note 10)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; shares issued and outstanding 0 and 0, respectively as of December 31, 2020 and June 30, 2020, respectively.
Common Stock, par value $.0001; 200,000,000 shares authorized; shares issued and outstanding 17,882,893 and 12,583,736, respectively as of December 31, 2020 and June 30, 2020.	1,788	1,259
Additional paid-in capital	246,532,284	215,024,216
Accumulated deficit	(133,841,404)	(120,010,179)
Total stockholders' equity	112,692,668	95,015,296
Total liabilities and stockholders' equity	166,742,096	152,836,330
Licensed Assets [Member]
Current assets
Finite-lived intangible assets, net	15,449,281	16,586,847
Patents and Tradenames [Member]
Current assets
Finite-lived intangible assets, net	10,197,112	11,081,048
Technology-Based Intangible Assets [Member]
Current assets
Finite-lived intangible assets, net	$ 20,051,666	$ 21,186,666

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Dec. 31, 2020	Jun. 30, 2020
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	17,882,893	12,583,736
Common stock, shares outstanding (in shares)	17,882,893	12,583,736

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Revenues
Product revenue, net	$ 15,147,034	$ 3,175,236	$ 28,667,280	$ 4,615,062
Operating expenses
Cost of sales	5,998,389	606,046	9,817,545	981,766
Research and development	286,572	66,675	469,437	144,695
Selling, general and administrative	12,852,614	6,516,160	24,342,983	11,662,603
Amortization of intangible assets	1,584,580	953,450	3,169,161	1,528,567
Total operating expenses	20,722,155	8,142,331	37,799,126	14,317,631
Loss from operations	(5,575,121)	(4,967,095)	(9,131,846)	(9,702,569)
Other (expense) income
Other (expense), net	(378,958)	(446,958)	(1,130,499)	(642,344)
Loss from change in fair value of contingent consideration	(3,313,656)		(2,411,333)
Gain from derecognition of contingent consideration		5,199,806		5,199,806
Gain from warrant derivative liability				1,830
Loss on debt exchange	(257,559)		(257,559)
Total other (expense) income	(3,950,173)	4,752,848	(4,699,378)	4,559,292
Net loss	$ (9,525,294)	$ (214,247)	$ (13,831,224)	$ (5,143,277)
Weighted average number of common shares outstanding (in shares)	13,281,904	1,753,815	12,717,180	1,642,599
Basic and diluted net loss per common share (in dollars per share)	$ (0.72)	$ (0.12)	$ (1.09)	$ (3.13)

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Series F Preferred Stock [Member]Preferred Stock [Member]	Series F Preferred Stock [Member]Common Stock [Member]	Series F Preferred Stock [Member]Additional Paid-in Capital [Member]	Series F Preferred Stock [Member]Retained Earnings [Member]	Series F Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
BALANCE (in shares) at Jun. 30, 2019						3,594,981	1,753,808
BALANCE at Jun. 30, 2019						$ 359	$ 176	$ 113,476,783	$ (106,389,500)	$ 7,087,818
Stock-based compensation								165,171		165,171
Securities converted for common stock (in shares)						(443,833)	44,384
Securities converted for common stock						$ (44)	$ 5	39
Net loss									(4,929,030)	(4,929,030)
BALANCE (in shares) at Sep. 30, 2019						3,151,148	1,798,192
BALANCE at Sep. 30, 2019						$ 315	$ 181	113,641,993	(111,318,530)	2,323,959
BALANCE (in shares) at Jun. 30, 2019						3,594,981	1,753,808
BALANCE at Jun. 30, 2019						$ 359	$ 176	113,476,783	(106,389,500)	7,087,818
Net loss										(5,143,277)
BALANCE (in shares) at Dec. 31, 2019						10,215,845	2,073,307
BALANCE at Dec. 31, 2019						$ 1,022	$ 209	128,621,786	(111,532,777)	17,090,240
BALANCE (in shares) at Sep. 30, 2019						3,151,148	1,798,192
BALANCE at Sep. 30, 2019						$ 315	$ 181	113,641,993	(111,318,530)	2,323,959
Stock-based compensation								162,264		162,264
Securities converted for common stock (in shares)						(2,751,148)	275,115
Securities converted for common stock						$ (275)	$ 28	247
Net loss									(214,247)	(214,247)
Issuance of stock (in shares)	10,000
Issuance of stock	$ 1		$ 5,249,483		$ 5,249,484
Warrants issued in connection with the private placement								4,008,866		4,008,866
Issuance of Series G preferred stock due to acquisition of the Cerecor portfolio of pediatrics therapeutics (in shares)						9,805,845
Issuance of Series G preferred stock due to acquisition of the Cerecor portfolio of pediatrics therapeutics						$ 981		5,558,933		5,559,914
Issuance costs					$ (741,650)
BALANCE (in shares) at Dec. 31, 2019						10,215,845	2,073,307
BALANCE at Dec. 31, 2019						$ 1,022	$ 209	128,621,786	(111,532,777)	17,090,240
BALANCE (in shares) at Jun. 30, 2020							12,583,736
BALANCE at Jun. 30, 2020							$ 1,259	215,024,216	(120,010,179)	95,015,296
Stock-based compensation								454,918		454,918
Net loss									(4,305,931)	(4,305,931)
Issuance costs								(101,537)		(101,537)
BALANCE (in shares) at Sep. 30, 2020							12,583,736
BALANCE at Sep. 30, 2020							$ 1,259	215,377,597	(124,316,110)	91,062,746
BALANCE (in shares) at Jun. 30, 2020							12,583,736
BALANCE at Jun. 30, 2020							$ 1,259	215,024,216	(120,010,179)	95,015,296
Net loss										(13,831,224)
BALANCE (in shares) at Dec. 31, 2020							17,882,893
BALANCE at Dec. 31, 2020							$ 1,788	246,532,284	(133,841,404)	112,692,668
BALANCE (in shares) at Sep. 30, 2020							12,583,736
BALANCE at Sep. 30, 2020							$ 1,259	215,377,597	(124,316,110)	91,062,746
Stock-based compensation								508,059		508,059
Securities converted for common stock (in shares)							130,081
Securities converted for common stock							$ 13	1,057,546		1,057,559
Net loss									(9,525,294)	(9,525,294)
Issuance of stock (in shares)							5,169,076
Issuance of stock							$ 516	28,316,928		28,317,444
Warrants issued in connection with the private placement								1,272,154		1,272,154
BALANCE (in shares) at Dec. 31, 2020							17,882,893
BALANCE at Dec. 31, 2020							$ 1,788	$ 246,532,284	$ (133,841,404)	$ 112,692,668

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($)	3 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Series F Preferred Stock [Member]
Issuance costs		$ 741,650
Issuance costs	$ 101,537

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020
Operating Activities
Net loss	$ (9,525,294)	$ (4,305,931)	$ (214,247)	$ (4,929,030)	$ (13,831,224)	$ (5,143,277)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation, amortization and accretion					4,012,909	2,157,540
Stock-based compensation expense					962,977	327,435
Loss from change in fair value of contingent consideration	3,313,656				2,411,333
(Gain) from derecognition of contingent consideration			(5,199,806)			(5,199,806)
Loss on sale of equipment					112,110
(Gain) on termination of lease					(343,185)
Loss on debt exchange	257,559				257,559
Changes in allowance for bad debt					147,627
Loss from change in fair value of CVR					899,987
Derivative income						(1,830)
Changes in operating assets and liabilities:
Increase in accounts receivable					(1,965,271)	(3,456,364)
Increase in inventory					(3,615,662)	(132,199)
Increase in prepaid expenses and other					(379,337)	(171,430)
Decrease (increase) in other current assets					2,295,055	(136,694)
(Decrease) increase in accounts payable and other					(3,136,163)	2,806,973
Increase in accrued liabilities					1,711,466	145,467
Decrease in accrued compensation					(576,824)	(62,729)
Decrease in fixed payment arrangements						(216,150)
Increase in contract liability					136,344
Decrease in deferred rent						(3,990)
Net cash used in operating activities					(10,900,299)	(9,087,054)
Investing Activities
Deposit					(3,923)
Contingent consideration payment					(42,760)	(104,635)
Note receivable						(1,350,000)
Purchase of assets						(4,500,000)
Net cash used in investing activities					(46,683)	(5,954,635)
Financing Activities
Issuance of preferred, common stock and warrants					32,249,652	10,000,000
Issuance cost related to registered offering					(4,292,781)	(741,650)
Payments made to borrowings					(272,727)
Payments made to fixed payment arrangements					(2,785,863)
Net cash provided by financing activities					24,898,281	9,258,350
Net change in cash, restricted cash and cash equivalents					13,951,299	(5,783,339)
Cash, restricted cash and cash equivalents at beginning of period		$ 48,333,307		$ 11,294,227	48,333,307	11,294,227	$ 11,294,227
Cash, restricted cash and cash equivalents at end of period	$ 62,284,606		$ 5,510,888		62,284,606	5,510,888	$ 48,333,307
Supplemental disclosures of cash and non-cash investing and financing transactions
Warrants issued to underwriters					356,139
Cash paid for interest					306,752	3,390
Fair value of right-to-use asset and related lease liability					43,082	412,691
Contingent consideration included in accounts payable						3,430
Debt exchange					1,057,559
Fixed payment arrangements included in accrued liabilities					1,050,000
Inventory swap					7,043,849
Acquisition costs included in accounts payable						59,014
Conversion of Convertible Preferred Stock into Common Stock [Member]
Supplemental disclosures of cash and non-cash investing and financing transactions
Exchange of convertible preferred stock into common stock						$ 44

Note 1 - Nature of Business, Fi

Note 1 - Nature of Business, Financial Condition, Basis of Presentation	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Nature of Business. August 9, 2002 June 8, 2015. The Primary Care Portfolio consists of (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12 The Pediatric Care Portfolio, acquired on November 1, 2019, ( two second On February 14, 2020, twenty Innovus's proprietary Beyond Human® On December 10, 2020, not December 31, 2020, 24% 76% $0.95 0.1088 February 5, 2021, 5.4 $44.2 In connection with the execution of the Merger Agreement, the Company and Neos have entered into a Commitment Letter (the “Bridge Commitment Letter”) for the Company to provide financing to Neos under an unsecured convertible note, in an aggregate amount of up to $5,000,000, 6.0% 2.0% 2.0% November 7, 2022. 0.00011 $100,000 In April 2020, 19 The Company recently established a purchasing relationship with a U.S. supplier of Emergency Use Authorization (EUA) authorized antigen tests. Antigen tests rapidly detect the presence of the SARS-CoV- 2 The Company's strategy is to continue building its portfolio of revenue-generating products, leveraging its commercial team's expertise to build leading brands within large therapeutic markets. Financial Condition. December 31, 2020 $62.3 Revenues for the three six December 31, 2020 $15.1 $28.7 $3.2 $4.6 December 31, 2019, 377% 521% six December 31, 2020 $10.9 $9.1 six December 31, 2019 As of the date of this Report, the Company expects costs for its current operations to increase modestly as the Company continues to integrate the acquisition of the Pediatrics Portfolio, Innovus and if approved by the Company's and Neos' shareholders, the Neos Merger, continues to focus on revenue growth through increasing product sales and additional acquisitions. The Company's current assets totaling approximately $92.5 December 31, 2020 may may no $29.6 three December 31, 2020, 0.4 4.8 0.3 December 15, 2020. December 10, 2020, $0.8 0.1 15 Between December 31, 2020 , and the filing date of this quarterly report on Form 10 has not common stock under the Company's at-the-market offering program. As of the date of this report, the Company has adequate capital resources to complete its near-term operating objectives. Since the Company has sufficient cash on-hand as of December 31, 2020 twelve no If the Company is unable to raise adequate capital in the future when it is required, the Company's management can adjust its operating plans to reduce the magnitude of the capital need under its existing operating plan. Some of the adjustments that could be made include delays of and reductions to commercial programs, reductions in headcount, narrowing the scope of the Company's commercial plans, or reductions to its research and development programs. Without sufficient operating capital, the Company could be required to relinquish rights to products or renegotiate to maintain such rights on less favorable terms than it would otherwise choose. This may Basis of Presentation. 10 June 30, 2020 December 31, 2020 not three six December 31, 2020 2019 On December 8, 2020, one 10 Interim Unaudited Condensed Consolidated Financial Statements. December 31, 2020 three six six December 31, 2020 2019 June 30, 2020 not not three six December 31, 2020 not Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent consideration, contingent value rights ("CVRs"), and fixed payment obligations at the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not Significant Accounting Policies The Company's significant accounting policies are discussed in Note 2—Summary no three December 31, 2020 Adoption of New Accounting Pronouncements Fair Value Measurements ( ASU 2018 13 ). August 2018, 2018 13, 820 2018 13 820, December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 July 1, 2020, June 30, 2021. 2018 13 3 3 Recent Accounting Pronouncements Financial Instruments Credit Losses ( ASU 2016 13 ). June 2016, 2016 13, December 15, 2019. October 2019, December 15, 2022. June 30, 2024. December 15, 2018, not 2016 13 no This Quarterly Report on Form 10 not not

Note 2 - Acquisitions

Note 2 - Acquisitions	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Business Combination Disclosure [Text Block]	2. The Pediatric Portfolio On October 10, 2019, November 1, 2019. four $4.5 980 not $2.7 $0.8 $3.5 In addition, the Company assumed Cerecor obligations due to an investor that include fixed and variable payments aggregating to $25.6 $0.1 November 2019 January 2021 $15 January 2021. 15% $0.1 January 2020, one $0.2 $9.5 February 12, 2026. June 2020, $15 January 2021 Further, certain of the products in the Pediatric Portfolio require royalty payments ranging from 12% 15% $1.8 not While no 805. The following table summarized the fair value of assets acquired and liabilities assumed at the date of acquisition. As of November 1, 2019 Consideration Cash and cash equivalents $ 4,500,000 Fair value of Series G Convertible Preferred Stock Total shares issued 9,805,845 Estimated fair value per share of Aytu common stock $ 0.567 Estimated fair value of equity consideration transferred 5,559,914 Total consideration transferred $ 10,059,914 Recognized amounts of identifiable assets acquired and liabilities assumed Inventory $ 459,123 Prepaid assets 1,743,555 Other current assets 2,525,886 Intangible assets - product marketing rights 22,700,000 Accrued liabilities (300,000 ) Accrued product program liabilities (6,683,932 ) Assumed fixed payment obligations $ (29,837,853 ) Total identifiable net assets (9,393,221 ) Goodwill $ 19,453,135 The fair values of intangible assets, including product technology rights were determined using variations of the income approach. Varying discount rates were also applied to the projected net cash flows. The Company believes the assumptions are representative of those a market participant would use in estimating fair value (see Note 9 The fair value of the net identifiable asset acquired was determined to be $22.7 ten Innovus Merger (Consumer Health Portfolio) On February 14, 2020, February 13, 2020. 380 $16 200 100% On March 31, 2020, first 120 $2.0 $24 December 31, 2019. $0.3 In addition, as part of the Merger, the Company assumed approximately $3.1 $0.8 $3.1 $2.2 180 February 14, 2020. Approximately $41 December 31, 2020 The following table summarized the preliminary fair value of assets acquired and liabilities assumed at the date of acquisition. These estimates are preliminary, pending final evaluation of certain assets and liabilities, and therefore, are subject to revisions that may As of February 14, 2020 Consideration Fair Value of Aytu Common Stock Total shares issued at close 3,810,393 Estimated fair value per share of Aytu common stock $ 0.756 Estimated fair value of equity consideration transferred $ 2,880,581 Fair value of Series H Convertible Preferred Stock Total shares issued 1,997,736 Estimated fair value per share of Aytu common stock $ 0.756 Estimated fair value of equity consideration transferred $ 1,510,288 Fair value of former Innovus warrants $ 15,315 Fair value of Contingent Value Rights $ 7,049,079 Forgiveness of Note Payable owed to the Company $ 1,350,000 Total consideration transferred $ 12,805,263 As of February 14, 2020 Total consideration transferred $ 12,805,263 Recognized amounts of identified assets acquired and liabilities assumed Cash and cash equivalents $ 390,916 Accounts receivable 278,826 Inventory 1,149,625 Prepaid expenses and other current assets 1,692,133 Other long-term assets 36,781 Right-to-use assets 328,410 Property, plant and equipment 190,393 Trademarks and patents 11,744,000 Accounts payable and accrued other expenses (7,202,309 ) Other current liabilities (629,601 ) Notes payable (3,056,361 ) Lease liability (754,822 ) Total identifiable assets $ 4,167,991 Goodwill $ 8,637,272 The fair values of intangible assets, including product distribution rights were determined using variations of the income approach, specifically the relief-from-royalties method. It also includes customer lists using an income approach utilizing a discounted cash flow model. Varying discount rates were also applied to the projected net cash flows. The CVRs were valued using a Monte-Carlo model. The Company believes the assumptions are representative of those a market participant would use in estimating fair value (see Note 10 The fair value of the net identifiable assets acquired was determined to be $11.7 1.5 10 Unaudited Pro Forma Information The following supplemental unaudited proforma financial information presents the Company's results as if the following acquisitions had occurred on July 1, 2019: ● Acquisition of the Pediatric Portfolio, effective November 1, 2019; ● Merger with Innovus effective February 14, 2020. The unaudited pro forma results have been prepared based on estimates and assumptions, which management believes are reasonable, however, the results are not July 1, 2019, Three Months Ended Six Months Ended December 31, 2020 December 31, 2019 December 31, 2020 December 31, 2019 Actual Pro forma Actual Pro forma (Unaudited) (Unaudited) (Unaudited) (Unaudited) Total revenues, net $ 15,147,034 $ 8,929,802 $ 28,667,280 $ 20,541,401 Net (loss) (9,525,294 ) (2,450,247 ) (13,831,224 ) (11,255,247 ) Net (loss) per share (aa) $ (0.72 ) $ (1.40 ) $ (1.09 ) $ (6.85 ) (aa) Pro forma net loss per share calculations excluded the impact of the issuance of the (i) Series G Convertible Preferred Stock and the, (ii) Series H Convertible Preferred Stock under the assumption those shares would continue to remain non-participatory during the periods reported above.

Note 3 - Revenue Recognition

Note 3 - Revenue Recognition	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenues by Geographic location . Three Months Ended Six Months Ended December 31, December 31, 2020 2019 2020 2019 (unaudited) (unaudited) (unaudited) (unaudited) U.S. $ 13,757,000 $ 3,047,000 $ 25,901,000 $ 4,309,000 International 1,390,000 128,000 2,766,000 306,000 Total net revenue $ 15,147,000 $ 3,175,000 $ 28,667,000 $ 4,615,000 Revenues by Product Portfolio. three six December 31, 2020 December 31, 2019 Three Months Ended December 31, Six Months Ended December 31, 2020 2019 2020 2019 Primary care and devices portfolio $ 4,097,000 $ 1,190,000 $ 7,130,000 $ 2,630,000 Pediatric portfolio 3,115,000 1,985,000 5,834,000 1,985,000 Consumer Health portfolio 7,935,000 - 15,703,000 - Total net revenue $ 15,147,000 $ 3,175,000 $ 28,667,000 $ 4,615,000

Note 4 - Inventories

Note 4 - Inventories	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventories consist of raw materials and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first first no first $0.1 $0.2 three six December 31, 2020 no three six December 31, 2019 Inventory balances consist of the following: As of As of December 31, June 30, 2020 2020 Raw materials $ 590,000 $ 397,000 Finished goods, net 5,981,000 9,603,000 $ 6,571,000 $ 10,000,000

Note 5 - Fixed Assets

Note 5 - Fixed Assets	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Fixed assets are recorded at cost and once placed in service, are depreciated on a straight-line basis over the estimated useful lives. Leasehold improvements are amortized over the shorter of the estimated economic life or related lease term. Fixed assets consist of the following: As of As of Estimated December 31, June 30, Useful Lives in years 2020 2020 Manufacturing equipment 2 5 $ 112,000 $ 112,000 Leasehold improvements 3 111,000 229,000 Office equipment, furniture and other 2 5 281,000 312,000 Lab equipment 3 5 90,000 90,000 Less accumulated depreciation and amortization (504,000 ) (484,000 ) Fixed assets, net $ 90,000 $ 259,000 During the six December 31, 2020 $0.1 Depreciation and amortization expense totaled $18,000 $16,000 three December 31, 2020 2019, $51,000 $32,000 six December 31, 2020 2019

Note 6 - Leases, Right-to-use A

Note 6 - Leases, Right-to-use Assets and Related Liabilities	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. The Company previously adopted the FASB issued ASU 2016 02, 842 July 1, 2019. 2016 02, July 1, 2019; 842; not As of December 31, 2020 Operating Finance 2021 (remaining 6 months) $ 37,000 $ 61,000 2022 18,000 124,000 2023 - 127,000 2024 - 35,000 2025 - 3,000 Total lease payments 55,000 350,000 Less: Imputed interest (39,000 ) Lease liabilities $ 311,000 Cash paid for amounts included in the measurement of finance lease liabilities for the six December 31, 2020 2019 $147,000 $63,000, As of December 31, 2020 2.28 8.0%. three December 31, 2020 2019 $90,000 $30,000. six December 31, 2020 2019 $160,000 $63,000, On August 28, 2020, September 30, 2020. April 30, 2023. two $44,306 $125,000 $20,881. $0.7 June 30, 2020 $343,000 six December 31, 2020 On October 1, 2020, one six ninety not

Note 7 - Intangible Assets - Am

Note 7 - Intangible Assets - Amortizable	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	7. Amortizable The Company currently holds the following intangible asset portfolios as of December 31, 2020 July 1, 2020; ( November 1, 2019 February 14, 2020, If acquired in an asset acquisition, the Company capitalized the acquisition cost of each licensed patent or tradename, which can include a combination of both upfront consideration, as well as the estimated future contingent consideration estimated at the acquisition date. If acquired in a business combination, the Company capitalizes the estimated fair value of the intangible asset or assets acquired, based primarily on a discounted cash flow model approach or relief-from-royalties model. The following table provides the summary of the Company's intangible assets as of December 31, 2020 June 30, 2020 December 31, 2020 Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Weighted-Average Remaining Life (in years) Licensed assets $ 23,649,000 $ (8,200,000 ) $ - $ 15,449,000 11.72 Acquired product technology right 22,700,000 (2,648,000 ) - 20,052,000 8.84 Acquired product distribution rights 11,354,000 (1,319,000 ) - 10,035,000 7.27 Acquired customer lists 390,000 (227,000 ) - 163,000 0.62 $ 58,093,000 $ (12,394,000 ) $ - $ 45,699,000 9.44 June 30, 2020 Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Weighted-Average Remaining Life (in years) Licensed assets $ 23,649,000 $ (7,062,000 ) $ - $ 16,587,000 11.88 MiOXSYS Patent 380,000 (185,000 ) (195,000 ) - - Acquired product technology right 22,700,000 (1,513,000 ) - 21,187,000 9.34 Acquired product distribution rights 11,354,000 (565,000 ) - 10,789,000 7.78 Acquired customer lists 390,000 (98,000 ) - 292,000 1.12 $ 58,473,000 $ (9,423,000 ) $ (195,000 ) $ 48,855,000 9.11 The following table summarizes the estimated future amortization expense to be recognized over the next five Amortization 2021 $ 3,157,000 2022 6,085,000 2023 6,045,000 2024 6,033,000 2025 4,480,000 Thereafter 19,899,000 $ 45,699,000 Certain of the Company's amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 20 $1.6 $0.9 three December 31, 2020 2019 $3.2 $1.5 six December 31, 2020 2019

Note 8 - Accrued Liabilities

Note 8 - Accrued Liabilities	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	8. Accrued liabilities consist of the following: As of As of December 31, June 30, 2020 2020 Accrued settlement expense $ 150,000 $ 315,000 Accrued program liabilities 1,386,000 959,000 Accrued product-related fees 2,332,000 2,471,000 Credit card liabilities 712,000 510,000 Medicaid liabilities 2,094,000 1,842,000 Return reserve 1,656,000 1,329,000 Sales taxes payable 175,000 175,000 Other accrued liabilities* 373,000 249,000 Total accrued liabilities $ 8,878,000 $ 7,850,000 * Other accrued liabilities consist of franchise tax, accounting fee, interest payable, merchant services charges, none five

Note 9 - Fair Value Considerati

Note 9 - Fair Value Considerations	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. The Company's asset and liability classified financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant derivative liability, and contingent consideration. The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on Monte-Carlo models. The valuation policies are determined by management, and the Company's Board of Directors is informed of any policy change. Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three Level 1: Level 2: Level 3: no The Company's assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company's policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented. Recurring Fair Value Measurements The following table presents the Company's financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2020 June 30, 2020 Fair Value Measurements at December 31, 2020 Fair Value at December 31, 2020 Quoted Priced in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Recurring: Contingent consideration 16,280,000 – – 16,280,000 CVR liability 6,472,000 – – 6,472,000 $ 22,752,000 – – $ 22,752,000 Fair Value Measurements at June 30, 2020 Fair Value at June 30, 2020 Quoted Priced in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Recurring: Contingent consideration 13,588,000 – – 13,588,000 CVR liability $ 5,572,000 – – $ 5,572,000 $ 19,160,000 – – $ 19,160,000 Contingent Consideration. 3 not As of November 2, 2018, $8.8 December 31,2020, $15.8 December 31, 2020 none no $3.0 November 2021, The contingent consideration related to the ZolpiMist royalty payments was valued at $2.6 June 11, 2018. December 31, 2020, $0.3 December 31, 2020 none no The Company recognized approximately $0.2 February 14, 2020 30% three six December 31, 2020 2019 $15,000 $28,000 no December 31, 2020 Contingent value rights. $16 470 March 31, 2020, 120 first $2 $24 2019 three six December 31, 2020 2019 $0.1 $0.8 not December 31, 2019. Summary of Level 3 The following table sets forth a summary of changes to those fair value measures using Level 3 three December 31, 2020 CVR Liability Contingent Consideration Balance as of June 30, 2020 $ 5,572,000 $ 13,588,000 Transfers into Level 3 – – Transfer out of Level 3 – – Total gains, losses, amortization or accretion in period – – Included in earnings $ 900,000 $ 2,735,000 Included in other comprehensive income – – Purchases, issues, sales and settlements – – Purchases – – Issues – – Sales – – Settlements – $ (43,000 ) Balance as of December 31, 2020 $ 6,472,000 $ 16,280,000 Significant Assumptions Contingent consideration. December 31, 2020, As of December 31, 2020 Contingent Consideration Credit risk assumption 19.10% Sales volatility 45.00% Credit spread 4.00% Time steps per year 1 Number of iterations 500 Contingent value rights. December 31, 2020 As of December 31, 2020 Contingent Value Rights Credit risk assumption 9.6% Time steps per year 30.00 Number of iterations 10,000

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and contingencies are described below and summarized by the following as of December 31, 2020 Total 2021 2022 2023 2024 2025 Thereafter Prescription database $ 1,278,000 $ 545,000 $ 733,000 - - - - Pediatric portfolio fixed payments and product minimums 15,825,000 1,650,000 3,300,000 3,300,000 3,300,000 3,300,000 975,000 Inventory purchase commitment 1,717,000 981,000 736,000 - - - - CVR liability 14,000,000 2,000,000 2,000,000 5,000,000 5,000,000 - - Product contingent liability 2,500,000 - - - - - 2,500,000 Product milestone payments 3,000,000 - 3,000,000 - - - - $ 38,320,000 $ 5,176,000 $ 9,769,000 $ 8,300,000 $ 8,300,000 $ 3,300,000 $ 3,475,000 Prescription Database In May 2016, $1.6 three January 2020, $0.6 Pediatric Portfolio Fixed Payments and Product Milestone The Company assumed two November 1, 2019 January 2021, $86,840, $15,000,000 January 2021. second $100,000 February 2026, $210,767 January 2020. On May 29, 2020, $15.0 In addition, the Company acquired a Supply and Distribution Agreement with Tris Pharma, Inc. ("TRIS"), (the “Karbinal Agreement”), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Karbinal Agreement was 20 23.5% third 23.5% 8.5%, 15% 2018 2019 The Karbinal Agreement make-whole $2,100,000 August 1 July 31, 70,000 2025. $30 70,000 2025. August $3.0 first $40.0 Inventory Purchase Commitment On May 1, 2020, 50 No. 207957 three 2022 $1.0 CVR Liability On February 14, 2020, February 13, 2020. first one On March 31, 2020, first 120 $2.0 $24.0 December 31, 2019. $0.3 June 30, 2020 No December 31, 2020 Product Contingent Liability In February 2015, 5 $0.5 December 31, 2020, $0.2 Product Milestone Payments In connection with the Company's intangible assets, Aytu has certain milestone payments, totaling $3.0 not 9

Note 11 - Capital Structure

Note 11 - Capital Structure	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. The Company has 200 $0.0001 50 $0.0001 December 31, 2020 June 30, 2020 17,882,893 12,583,736 zero Included in the common stock outstanding are 365,869 In June 2020, 430,230 $6.8 $0.2 December 31, 2020 not three September 30, 2020. three December 31, 2020, 352,912 $3.6 $0.1 In July 2020, $1.5 March 10, 12, 19 “March 92,302 92,302 $15.99 March 2020 one $356,000 On December 10, 2020, $0.8 130,081 15 On December 10, 2020, 4,166,667 $0.0001 $6.00 30 625,000 4,791,667 311,458 311,458 $7.50 125% five

Note 12 - Equity Incentive Plan

Note 12 - Equity Incentive Plan	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Share-based Compensation Plans On June 1, 2015, 2015 “2015 July 2017, 3.0 2015 2015 February 13, 2020, 5.0 2015 December 31, 2020 4,560,864 2015 Stock Options Employee Stock Options: The fair value of the options is calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. There were no three six December 31, 2020 2019 Stock option activity is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life in Years Aggregate Intrinsic Value Outstanding June 30, 2020 76,614 $ 19.39 9.67 $ - Granted - - Exercised - - Forfeited/Cancelled (3,187 ) - Expired (2 ) - Outstanding December 31, 2020 73,425 19.71 9.08 - Exercisable at December 31, 2020 9,095 $ 67.62 7.81 $ - As of December 31, 2020 $494,000 2.68 Restricted Stock Restricted stock activity is as follows: Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life in Years Unvested at June 30, 2020 418,454 $ 14.69 6.4 Granted Vested (52,743 ) Forfeited Unvested at December 31, 2020 365,711 $ 15.66 6.3 Under the 2015 $4.3 December 31, 2020 6.3 158 2015 July 2026. $1.1 December 31, 2020 5.5 Stock-based compensation expense related to the fair value of stock options and restricted stock was included in the statements of operations as selling, general and administrative expenses as set forth in the table below: Three Months Ended December 31, Six Months Ended December 31, Selling, general and administrative: 2020 2019 2020 2019 Stock options $ 94,000 $ 2,000 $ 166,000 $ 7,000 Restricted stock 414,000 160,000 797,000 320,000 Total stock-based compensation expense $ 508,000 $ 162,000 $ 963,000 $ 327,000

Note 13 - Warrants

Note 13 - Warrants	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Warrants or Rights Disclosure [Text Block]	13. In July 2020, 92,302 $15.99 March one $356,000 On December 15, 2020, 311,458 $7.50 December 15, 2020 $1.3 Significant assumptions in valuing the warrants issued during the quarter are as follows: Warrants Issued Three Months Ended December 31, 2020 Expected volatility 100 % Equivalent term (years) 5.0 Risk-free rate 37 % Dividend yield 0.00 % A summary of equity-based warrants is as follows: Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life in Years Outstanding June 30, 2020 2,288,528 $ 30.26 2.00 Warrants issued 403,760 Warrants expired (842 ) Warrants exercised - Outstanding December 31, 2020 2,691,446 $ 26.94 1.65

Note 14 - Net Loss Per Common S

Note 14 - Net Loss Per Common Share	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	14. Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. For each three 2020 2019, not The following table sets-forth securities that could be potentially dilutive, but as of the three six December 31, 2020 2019 Three Months Ended December 31, 2020 2019 Warrants to purchase common stock - liability classified 24,105 24,105 Warrant to purchase common stock - equity classified (Note 13) 2,691,446 1,621,891 Employee stock options (Note 12) 73,425 156 Employee unvested restricted stock (Note 12) 365,869 234,261 Convertible preferred stock (Note 11) - 315,115 3,154,845 2,195,528

Note 15 - Notes Payable

Note 15 - Notes Payable	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	15. The Aytu BioScience Note. February 27, 2020, $0.8 $0.6 eight November 1, 2020, $0.2 fourth 2020. three six December 31, 2020 2019 $15,000 $70,000, no 2019. December 10, 2020, 130,081 $0.3 $0.8 December 31, 2020. The Innovus Notes. January 9, 2020, $0.4 $0.5 twelve $45,000. December 31, 2020 , the net balance of the note was $41,000.

Note 16 - Segment Reporting

Note 16 - Segment Reporting	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	16. The Company's chief operating decision maker (the “CODM”), who is the Company's Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance. The Company manages and aggregates its operational and financial information in accordance with two Three months Ended December 31, Six Months Ended December 31, 2020 2019 2020 2019 Consolidated revenue: Aytu BioScience $ 7,212,000 $ 3,175,000 $ 13,000,000 $ 4,615,000 Aytu Consumer Health 7,935,000 - 16,000,000 - Consolidated revenue 15,147,000 3,175,000 29,000,000 4,615,000 Consolidated net loss: Aytu BioScience (8,267,000 ) (214,000 ) (11,218,000 ) (5,143,000 ) Aytu Consumer Health (1,258,000 ) - (2,613,000 ) - Consolidated net loss (9,525,000 ) (214,000 ) (13,831,000 ) (5,143,000 ) As of As of December 31, June 30, 2020 2020 Total assets: Aytu BioScience $ 140,647,000 $ 126,267,000 Aytu Consumer Health 26,095,000 26,569,000 Total assets $ 166,742,000 $ 152,836,000

Note 17 - Related Party Transac

Note 17 - Related Party Transactions	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	17. Tris Pharma, Inc. On November 2, 2018, November 1, 2019, 2 10 $1.9 $0.2 three December 31, 2020 2019 $24.1 $24.8 December 31, 2020 2019 n October 2020, $1.6

Note 18 - Subsequent Events

Note 18 - Subsequent Events	6 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	18. Except for below, see Footnote 1 December 31, 2020 10 MiOXSYS ® On January 20, 2021, ® Under the MiOXSYS Agreement, Avrio Genetics will purchase existing inventory, commercialize, and market the Product under a royalty on Product net sales with a minimum annual payment fee structure for a term of ten 10

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Financial Condition [Policy Text Block]	Financial Condition. December 31, 2020 $62.3 Revenues for the three six December 31, 2020 $15.1 $28.7 $3.2 $4.6 December 31, 2019, 377% 521% six December 31, 2020 $10.9 $9.1 six December 31, 2019 As of the date of this Report, the Company expects costs for its current operations to increase modestly as the Company continues to integrate the acquisition of the Pediatrics Portfolio, Innovus and if approved by the Company's and Neos' shareholders, the Neos Merger, continues to focus on revenue growth through increasing product sales and additional acquisitions. The Company's current assets totaling approximately $92.5 December 31, 2020 may may no $29.6 three December 31, 2020, 0.4 4.8 0.3 December 15, 2020. December 10, 2020, $0.8 0.1 15 Between December 31, 2020 , and the filing date of this quarterly report on Form 10 has not common stock under the Company's at-the-market offering program. As of the date of this report, the Company has adequate capital resources to complete its near-term operating objectives. Since the Company has sufficient cash on-hand as of December 31, 2020 twelve no If the Company is unable to raise adequate capital in the future when it is required, the Company's management can adjust its operating plans to reduce the magnitude of the capital need under its existing operating plan. Some of the adjustments that could be made include delays of and reductions to commercial programs, reductions in headcount, narrowing the scope of the Company's commercial plans, or reductions to its research and development programs. Without sufficient operating capital, the Company could be required to relinquish rights to products or renegotiate to maintain such rights on less favorable terms than it would otherwise choose. This may
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation. 10 June 30, 2020 December 31, 2020 not three six December 31, 2020 2019 On December 8, 2020, one 10
Consolidation, Policy [Policy Text Block]	Interim Unaudited Condensed Consolidated Financial Statements. December 31, 2020 three six six December 31, 2020 2019 June 30, 2020 not not three six December 31, 2020 not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent consideration, contingent value rights ("CVRs"), and fixed payment obligations at the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not
New Accounting Pronouncements, Policy [Policy Text Block]	Significant Accounting Policies The Company's significant accounting policies are discussed in Note 2—Summary no three December 31, 2020 Adoption of New Accounting Pronouncements Fair Value Measurements ( ASU 2018 13 ). August 2018, 2018 13, 820 2018 13 820, December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 July 1, 2020, June 30, 2021. 2018 13 3 3 Recent Accounting Pronouncements Financial Instruments Credit Losses ( ASU 2016 13 ). June 2016, 2016 13, December 15, 2019. October 2019, December 15, 2022. June 30, 2024. December 15, 2018, not 2016 13 no This Quarterly Report on Form 10 not not

Note 2 - Acquisitions (Tables)

Note 2 - Acquisitions (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	As of November 1, 2019 Consideration Cash and cash equivalents $ 4,500,000 Fair value of Series G Convertible Preferred Stock Total shares issued 9,805,845 Estimated fair value per share of Aytu common stock $ 0.567 Estimated fair value of equity consideration transferred 5,559,914 Total consideration transferred $ 10,059,914 Recognized amounts of identifiable assets acquired and liabilities assumed Inventory $ 459,123 Prepaid assets 1,743,555 Other current assets 2,525,886 Intangible assets - product marketing rights 22,700,000 Accrued liabilities (300,000 ) Accrued product program liabilities (6,683,932 ) Assumed fixed payment obligations $ (29,837,853 ) Total identifiable net assets (9,393,221 ) Goodwill $ 19,453,135 As of February 14, 2020 Consideration Fair Value of Aytu Common Stock Total shares issued at close 3,810,393 Estimated fair value per share of Aytu common stock $ 0.756 Estimated fair value of equity consideration transferred $ 2,880,581 Fair value of Series H Convertible Preferred Stock Total shares issued 1,997,736 Estimated fair value per share of Aytu common stock $ 0.756 Estimated fair value of equity consideration transferred $ 1,510,288 Fair value of former Innovus warrants $ 15,315 Fair value of Contingent Value Rights $ 7,049,079 Forgiveness of Note Payable owed to the Company $ 1,350,000 Total consideration transferred $ 12,805,263 As of February 14, 2020 Total consideration transferred $ 12,805,263 Recognized amounts of identified assets acquired and liabilities assumed Cash and cash equivalents $ 390,916 Accounts receivable 278,826 Inventory 1,149,625 Prepaid expenses and other current assets 1,692,133 Other long-term assets 36,781 Right-to-use assets 328,410 Property, plant and equipment 190,393 Trademarks and patents 11,744,000 Accounts payable and accrued other expenses (7,202,309 ) Other current liabilities (629,601 ) Notes payable (3,056,361 ) Lease liability (754,822 ) Total identifiable assets $ 4,167,991 Goodwill $ 8,637,272
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Ended Six Months Ended December 31, 2020 December 31, 2019 December 31, 2020 December 31, 2019 Actual Pro forma Actual Pro forma (Unaudited) (Unaudited) (Unaudited) (Unaudited) Total revenues, net $ 15,147,034 $ 8,929,802 $ 28,667,280 $ 20,541,401 Net (loss) (9,525,294 ) (2,450,247 ) (13,831,224 ) (11,255,247 ) Net (loss) per share (aa) $ (0.72 ) $ (1.40 ) $ (1.09 ) $ (6.85 )

Note 3 - Revenue Recognition (T

Note 3 - Revenue Recognition (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended Six Months Ended December 31, December 31, 2020 2019 2020 2019 (unaudited) (unaudited) (unaudited) (unaudited) U.S. $ 13,757,000 $ 3,047,000 $ 25,901,000 $ 4,309,000 International 1,390,000 128,000 2,766,000 306,000 Total net revenue $ 15,147,000 $ 3,175,000 $ 28,667,000 $ 4,615,000
Disaggregation of Revenue [Table Text Block]	Three Months Ended December 31, Six Months Ended December 31, 2020 2019 2020 2019 Primary care and devices portfolio $ 4,097,000 $ 1,190,000 $ 7,130,000 $ 2,630,000 Pediatric portfolio 3,115,000 1,985,000 5,834,000 1,985,000 Consumer Health portfolio 7,935,000 - 15,703,000 - Total net revenue $ 15,147,000 $ 3,175,000 $ 28,667,000 $ 4,615,000

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of As of December 31, June 30, 2020 2020 Raw materials $ 590,000 $ 397,000 Finished goods, net 5,981,000 9,603,000 $ 6,571,000 $ 10,000,000

Note 5 - Fixed Assets (Tables)

Note 5 - Fixed Assets (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of As of Estimated December 31, June 30, Useful Lives in years 2020 2020 Manufacturing equipment 2 5 $ 112,000 $ 112,000 Leasehold improvements 3 111,000 229,000 Office equipment, furniture and other 2 5 281,000 312,000 Lab equipment 3 5 90,000 90,000 Less accumulated depreciation and amortization (504,000 ) (484,000 ) Fixed assets, net $ 90,000 $ 259,000

Note 6 - Leases, Right-to-use_2

Note 6 - Leases, Right-to-use Assets and Related Liabilities (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Lessee, Lease Liability, Maturity [Table Text Block]	Operating Finance 2021 (remaining 6 months) $ 37,000 $ 61,000 2022 18,000 124,000 2023 - 127,000 2024 - 35,000 2025 - 3,000 Total lease payments 55,000 350,000 Less: Imputed interest (39,000 ) Lease liabilities $ 311,000

Note 7 - Intangible Assets - _2

Note 7 - Intangible Assets - Amortizable (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2020 Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Weighted-Average Remaining Life (in years) Licensed assets $ 23,649,000 $ (8,200,000 ) $ - $ 15,449,000 11.72 Acquired product technology right 22,700,000 (2,648,000 ) - 20,052,000 8.84 Acquired product distribution rights 11,354,000 (1,319,000 ) - 10,035,000 7.27 Acquired customer lists 390,000 (227,000 ) - 163,000 0.62 $ 58,093,000 $ (12,394,000 ) $ - $ 45,699,000 9.44 June 30, 2020 Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Weighted-Average Remaining Life (in years) Licensed assets $ 23,649,000 $ (7,062,000 ) $ - $ 16,587,000 11.88 MiOXSYS Patent 380,000 (185,000 ) (195,000 ) - - Acquired product technology right 22,700,000 (1,513,000 ) - 21,187,000 9.34 Acquired product distribution rights 11,354,000 (565,000 ) - 10,789,000 7.78 Acquired customer lists 390,000 (98,000 ) - 292,000 1.12 $ 58,473,000 $ (9,423,000 ) $ (195,000 ) $ 48,855,000 9.11
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization 2021 $ 3,157,000 2022 6,085,000 2023 6,045,000 2024 6,033,000 2025 4,480,000 Thereafter 19,899,000 $ 45,699,000

Note 8 - Accrued Liabilities (T

Note 8 - Accrued Liabilities (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of As of December 31, June 30, 2020 2020 Accrued settlement expense $ 150,000 $ 315,000 Accrued program liabilities 1,386,000 959,000 Accrued product-related fees 2,332,000 2,471,000 Credit card liabilities 712,000 510,000 Medicaid liabilities 2,094,000 1,842,000 Return reserve 1,656,000 1,329,000 Sales taxes payable 175,000 175,000 Other accrued liabilities* 373,000 249,000 Total accrued liabilities $ 8,878,000 $ 7,850,000

Note 9 - Fair Value Considera_2

Note 9 - Fair Value Considerations (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at December 31, 2020 Fair Value at December 31, 2020 Quoted Priced in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Recurring: Contingent consideration 16,280,000 – – 16,280,000 CVR liability 6,472,000 – – 6,472,000 $ 22,752,000 – – $ 22,752,000 Fair Value Measurements at June 30, 2020 Fair Value at June 30, 2020 Quoted Priced in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Recurring: Contingent consideration 13,588,000 – – 13,588,000 CVR liability $ 5,572,000 – – $ 5,572,000 $ 19,160,000 – – $ 19,160,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	CVR Liability Contingent Consideration Balance as of June 30, 2020 $ 5,572,000 $ 13,588,000 Transfers into Level 3 – – Transfer out of Level 3 – – Total gains, losses, amortization or accretion in period – – Included in earnings $ 900,000 $ 2,735,000 Included in other comprehensive income – – Purchases, issues, sales and settlements – – Purchases – – Issues – – Sales – – Settlements – $ (43,000 ) Balance as of December 31, 2020 $ 6,472,000 $ 16,280,000
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	As of December 31, 2020 Contingent Consideration Credit risk assumption 19.10% Sales volatility 45.00% Credit spread 4.00% Time steps per year 1 Number of iterations 500 As of December 31, 2020 Contingent Value Rights Credit risk assumption 9.6% Time steps per year 30.00 Number of iterations 10,000

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Contractual Obligation, Fiscal Year Maturity [Table Text Block]	Total 2021 2022 2023 2024 2025 Thereafter Prescription database $ 1,278,000 $ 545,000 $ 733,000 - - - - Pediatric portfolio fixed payments and product minimums 15,825,000 1,650,000 3,300,000 3,300,000 3,300,000 3,300,000 975,000 Inventory purchase commitment 1,717,000 981,000 736,000 - - - - CVR liability 14,000,000 2,000,000 2,000,000 5,000,000 5,000,000 - - Product contingent liability 2,500,000 - - - - - 2,500,000 Product milestone payments 3,000,000 - 3,000,000 - - - - $ 38,320,000 $ 5,176,000 $ 9,769,000 $ 8,300,000 $ 8,300,000 $ 3,300,000 $ 3,475,000

Note 12 - Equity Incentive Pl_2

Note 12 - Equity Incentive Plan (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life in Years Aggregate Intrinsic Value Outstanding June 30, 2020 76,614 $ 19.39 9.67 $ - Granted - - Exercised - - Forfeited/Cancelled (3,187 ) - Expired (2 ) - Outstanding December 31, 2020 73,425 19.71 9.08 - Exercisable at December 31, 2020 9,095 $ 67.62 7.81 $ -
Nonvested Restricted Stock Shares Activity [Table Text Block]	Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Life in Years Unvested at June 30, 2020 418,454 $ 14.69 6.4 Granted Vested (52,743 ) Forfeited Unvested at December 31, 2020 365,711 $ 15.66 6.3
Share-based Payment Arrangement, Cost by Plan [Table Text Block]	Three Months Ended December 31, Six Months Ended December 31, Selling, general and administrative: 2020 2019 2020 2019 Stock options $ 94,000 $ 2,000 $ 166,000 $ 7,000 Restricted stock 414,000 160,000 797,000 320,000 Total stock-based compensation expense $ 508,000 $ 162,000 $ 963,000 $ 327,000

Note 13 - Warrants (Tables)

Note 13 - Warrants (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Warrant and Rights Assumptions [Table Text Block]	Warrants Issued Three Months Ended December 31, 2020 Expected volatility 100 % Equivalent term (years) 5.0 Risk-free rate 37 % Dividend yield 0.00 %
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life in Years Outstanding June 30, 2020 2,288,528 $ 30.26 2.00 Warrants issued 403,760 Warrants expired (842 ) Warrants exercised - Outstanding December 31, 2020 2,691,446 $ 26.94 1.65

Note 14 - Net Loss Per Common_2

Note 14 - Net Loss Per Common Share (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended December 31, 2020 2019 Warrants to purchase common stock - liability classified 24,105 24,105 Warrant to purchase common stock - equity classified (Note 13) 2,691,446 1,621,891 Employee stock options (Note 12) 73,425 156 Employee unvested restricted stock (Note 12) 365,869 234,261 Convertible preferred stock (Note 11) - 315,115 3,154,845 2,195,528

Note 16 - Segment Reporting (Ta

Note 16 - Segment Reporting (Tables)	6 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three months Ended December 31, Six Months Ended December 31, 2020 2019 2020 2019 Consolidated revenue: Aytu BioScience $ 7,212,000 $ 3,175,000 $ 13,000,000 $ 4,615,000 Aytu Consumer Health 7,935,000 - 16,000,000 - Consolidated revenue 15,147,000 3,175,000 29,000,000 4,615,000 Consolidated net loss: Aytu BioScience (8,267,000 ) (214,000 ) (11,218,000 ) (5,143,000 ) Aytu Consumer Health (1,258,000 ) - (2,613,000 ) - Consolidated net loss (9,525,000 ) (214,000 ) (13,831,000 ) (5,143,000 ) As of As of December 31, June 30, 2020 2020 Total assets: Aytu BioScience $ 140,647,000 $ 126,267,000 Aytu Consumer Health 26,095,000 26,569,000 Total assets $ 166,742,000 $ 152,836,000

Note 1 - Nature of Business, _2

Note 1 - Nature of Business, Financial Condition, Basis of Presentation (Details Textual)	Dec. 15, 2020shares	Dec. 10, 2020USD ($)$ / shares	Dec. 08, 2020	Feb. 11, 2021shares	Jun. 30, 2020USD ($)shares	Dec. 31, 2020USD ($)shares	Sep. 30, 2020shares	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)	Feb. 05, 2021USD ($)shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance						$ 62,300,000			$ 62,300,000
Revenue from Contract with Customer, Including Assessed Tax						15,147,034		$ 3,175,236	$ 28,667,280	$ 4,615,062
Increase (Decrease) in Revenues, Percentage									377.00%	521.00%
Net Cash Provided by (Used in) Operating Activities, Total									$ (10,900,299)	$ (9,087,054)
Assets, Current, Total					$ 74,965,772	92,537,465			$ 92,537,465
Proceeds from Issuance of Common Stock						$ 29,600,000
Class of Warrant or Right, Issued During Period (in shares) | shares									403,760
Debt Conversion, Converted Instrument, Amount									$ 1,057,559
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			10
Conversion of Debt to Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 800,000
Debt Conversion, Converted Instrument, Amount		100,000
Placement Agent Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares) | shares	300,000
At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares					430,230	352,912	0
December 15, 2020 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	4,800,000
Bridge Commitment Letter [Member]
Debt Instrument, Face Amount		$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Debt Instrument, Increase in Stated Rate Upon Default, Percentage		2.00%
Subsequent Event [Member] | At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares				0
Neos Therapeutics, Inc. [Member]
Merger Agreement, Exercise Price of Stock Options (in dollars per share) | $ / shares		$ 0.95
Merger Agreement, Exchange Ratio		0.1088
Merger Agreement, Reduction in Exchange Ratio Per $100,000 of Financing Funded		0.00011
Neos Therapeutics, Inc. [Member] | Subsequent Event [Member]
Merger Agreement, Shares to be Issued, Shares (in shares) | shares											5,400,000
Merger Agreement, Shares to be Issued, Value											$ 44,200,000
Neo Stockholders [Member]
Common Stock Ownership, Percent		24.00%
Existing Company Stockholders [Member]
Common Stock Ownership, Percent		76.00%

Note 2 - Acquisitions (Details

Note 2 - Acquisitions (Details Textual) - USD ($)	Mar. 31, 2020	Feb. 14, 2020	Feb. 13, 2020	Nov. 01, 2019	Jun. 30, 2020	Jan. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020
Gain (Loss) from Change in Fair Value of CVR									$ (899,987)
Innovus Pharmaceuticals [Member]
Noncontrolling Interest, Ownership Percentage by Parent			100.00%
The Pediatric Portfolio [Member]
Payments to Acquire Businesses, Gross				$ 4,500,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)				9,805,845
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Minimum Annual Royalties				$ 1,800,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total				$ 22,700,000
Finite-Lived Intangible Asset, Useful Life (Year)				10 years
The Pediatric Portfolio [Member] | Minimum [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Royalty Payments, Percentage of Revenues				12.00%
The Pediatric Portfolio [Member] | Maximum [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Royalty Payments, Percentage of Revenues				15.00%
The Pediatric Portfolio [Member] | Cerecor, Inc. [Member]
Business Combination, Consideration Transferred, Liabilities Incurred, Medicaid Rebates				$ 2,700,000
Business Combination, Consideration Transferred, Liabilities Incurred, Product Returns				800,000
Business Combination, Consideration Transferred, Liabilities Incurred				3,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Fixed and Variable Payments to Investor				25,600,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Fixed Monthly Payments to Investor				100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Fixed Monthly Payments to Investor				$ 15,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Monthly Variable Payments to Investor, Percentage of Revenues				15.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Monthly Minimum Variable Payments to Investor				$ 100,000
Payments for Variable Monthly Obligation to Investor						$ 200,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Variable Payments to Investor				$ 9,500,000
Payments for Fixed Obligations to Investor					$ 15,000,000
The Pediatric Portfolio [Member] | Series G Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)				980,000
Innovus Pharmaceuticals [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		3,810,393	380,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 11,744,000	$ 11,700,000
Business Combination, Consideration Transferred, Contingent Value Rights		7,049,079	16,000,000
Stock Issued During Period, Shares, Contingent Value Rights (in shares)	120,000
Stock Issued During Period, Value, Contingent Value Rights	$ 2,000,000
Business Combination, Contingent Value Rights, First Revenue Milestone	24,000,000
Gain (Loss) from Change in Fair Value of CVR	$ 300,000						$ (100,000)	$ (100,000)	(800,000)	$ (800,000)	$ 300,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			3,100,000
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation		$ 754,822	800,000
Innovus Pharmaceuticals [Member] | Notes Payable, Other Payables [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt							$ 41,000		$ 41,000
Innovus Pharmaceuticals [Member] | Conversion of Notes Payable into Common Stock [Member]
Debt Conversion, Original Debt, Amount			$ 2,200,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)			180,000
Innovus Pharmaceuticals [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			1 year 182 days
Innovus Pharmaceuticals [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			10 years
Innovus Pharmaceuticals [Member] | Series H Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		1,997,736
Stock Issued During Period, Shares, Exercise of Warrants (in shares)			200,000

Note 2 - Acquisitions - Prelimi

Note 2 - Acquisitions - Preliminary Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Feb. 14, 2020	Feb. 13, 2020	Nov. 01, 2019	Dec. 31, 2020	Jun. 30, 2020
Goodwill				$ 28,090,407	$ 28,090,407
Innovus Pharmaceuticals [Member]
Total shares issued (in shares)	3,810,393	380,000
Estimated fair value per share of Aytu common stock (in dollars per share)	$ 0.756
Estimated fair value of equity consideration transferred	$ 2,880,581
Total consideration transferred	12,805,263
Inventory	1,149,625
Prepaid assets	1,692,133
Intangible assets - product marketing rights	11,744,000	$ 11,700,000
Accrued liabilities	7,202,309
Total identifiable net assets	4,167,991
Goodwill	8,637,272
Fair value of former Innovus warrants	15,315
Fair value of Contingent Value Rights	7,049,079	16,000,000
Forgiveness of Note Payable owed to the Company	1,350,000
Total consideration transferred	12,805,263
Cash and cash equivalents	390,916
Accounts receivable	278,826
Other long-term assets	36,781
Right-to-use assets	328,410
Property, plant and equipment	190,393
Other current liabilities	629,601
Notes payable	3,056,361
Lease liability	$ 754,822	$ 800,000
Innovus Pharmaceuticals [Member] | Series H Preferred Stock [Member]
Total shares issued (in shares)	1,997,736
Estimated fair value per share of Aytu common stock (in dollars per share)	$ 0.756
Estimated fair value of equity consideration transferred	$ 1,510,288
The Pediatric Portfolio [Member]
Cash and cash equivalents			$ 4,500,000
Total shares issued (in shares)			9,805,845
Estimated fair value per share of Aytu common stock (in dollars per share)			$ 0.567
Estimated fair value of equity consideration transferred			$ 5,559,914
Total consideration transferred			10,059,914
Inventory			459,123
Prepaid assets			1,743,555
Other current assets			2,525,886
Intangible assets - product marketing rights			22,700,000
Accrued liabilities			300,000
Accrued product program liabilities			6,683,932
Assumed fixed payment obligations			29,837,853
Total identifiable net assets			9,393,221
Goodwill			19,453,135
Total consideration transferred			$ 10,059,914

Note 2 - Acquisitions - Unaudit

Note 2 - Acquisitions - Unaudited Pro Forma Results (Details) - USD ($)		3 Months Ended		6 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Total revenues, net		$ 15,147,034		$ 28,667,280
Total revenues, net			$ 8,929,802		$ 20,541,401
Net (loss)		$ (9,525,294)		$ (13,831,224)
Net (loss)			$ (2,450,247)		$ (11,255,247)
Net (loss) per share (aa) (in dollars per share)	[1]	$ (0.72)	$ (1.40)	$ (1.09)	$ (6.85)
[1]	Pro forma net loss per share calculations excluded the impact of the issuance of the (i) Series G Convertible Preferred Stock and the, (ii) Series H Convertible Preferred Stock under the assumption those shares would continue to remain non-participatory during the periods reported above.

Note 3 - Revenue Recognition -

Note 3 - Revenue Recognition - Revenues by Geographic Location (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Total net revenue	$ 15,147,034	$ 3,175,236	$ 28,667,280	$ 4,615,062
UNITED STATES
Total net revenue	13,757,000	3,047,000	25,901,000	4,309,000
Non-US [Member]
Total net revenue	$ 1,390,000	$ 128,000	$ 2,766,000	$ 306,000

Note 3 - Revenue Recognition _2

Note 3 - Revenue Recognition - Revenues by Product Portfolio (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Total net revenue	$ 15,147,034	$ 3,175,236	$ 28,667,280	$ 4,615,062
Primary Care and Devices [Member]
Total net revenue	4,097,000	1,190,000	7,130,000	2,630,000
Pediatric [Member]
Total net revenue	3,115,000	1,985,000	5,834,000	1,985,000
Consumer Health [Member]
Total net revenue	$ 7,935,000		$ 15,703,000

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 30, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Inventory Write-down	$ 100	$ 0	$ 200	$ 0

Note 4 - Inventories - Inventor

Note 4 - Inventories - Inventory Balances (Details) - USD ($)	Dec. 31, 2020	Jun. 30, 2020
Raw materials	$ 590,000	$ 397,000
Finished goods, net	5,981,000	9,603,000
Inventory, Net, Total	$ 6,571,254	$ 9,999,441

Note 5 - Fixed Assets (Details

Note 5 - Fixed Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Gain (Loss) on Disposition of Property Plant Equipment, Total			$ (112,110)
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 18,000	$ 16,000	$ 51,000	$ 32,000

Note 5 - Fixed Assets - Fixed A

Note 5 - Fixed Assets - Fixed Assets (Details) - USD ($)	6 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
Less accumulated depreciation and amortization	$ (504,000)	$ (484,000)
Fixed assets, net	89,663	258,516
Manufacturing Equipment [Member]
Fixed assets, gross	$ 112,000	112,000
Manufacturing Equipment [Member] | Minimum [Member]
Estimated useful life (Year)	2 years
Manufacturing Equipment [Member] | Maximum [Member]
Estimated useful life (Year)	5 years
Leasehold Improvements [Member]
Estimated useful life (Year)	3 years
Fixed assets, gross	$ 111,000	229,000
Office Equipment, Furniture and Other [Member]
Fixed assets, gross	$ 281,000	312,000
Office Equipment, Furniture and Other [Member] | Minimum [Member]
Estimated useful life (Year)	2 years
Office Equipment, Furniture and Other [Member] | Maximum [Member]
Estimated useful life (Year)	5 years
Lab Equipment [Member]
Fixed assets, gross	$ 90,000	$ 90,000
Lab Equipment [Member] | Minimum [Member]
Estimated useful life (Year)	3 years
Lab Equipment [Member] | Maximum [Member]
Estimated useful life (Year)	5 years

Note 6 - Leases, Right-to-use_3

Note 6 - Leases, Right-to-use Assets and Related Liabilities (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Oct. 01, 2020	Aug. 28, 2020	Jun. 30, 2020
Operating Lease, Payments			$ 147,000	$ 63,000
Operating Lease, Weighted Average Remaining Lease Term (Year)	2 years 102 days		2 years 102 days
Operating Lease, Weighted Average Discount Rate, Percent	8.00%		8.00%
Operating Lease, Expense	$ 90,000	$ 30,000	$ 160,000	63,000
Gain (Loss) on Termination of Lease			343,185
Lease for Warehouse Space in Carlsbad, CA [Member]
Lessee, Operating Lease, Term of Contract (Year)					1 year
Innovus Pharmaceuticals [Member]
Lessee, Operating Lease, Termination Agreement, Two Months Rent						$ 44,306
Lessee, Operating Lease, Termination Agreement, Additional Fee						125,000
Security Deposit						$ 20,881
Operating Lease, Liability, Total							$ 700,000
Gain (Loss) on Termination of Lease			$ 343,000

Note 6 - Leases, Right-to-use_4

Note 6 - Leases, Right-to-use Assets and Related Liabilities - Maturities of Lease Liabilities (Details)	Dec. 31, 2020USD ($)
2021 (remaining 6 months), operating	$ 37,000
2021 (remaining 6 months), finance	61,000
2022, operating	18,000
2022, finance	124,000
2023, operating
2023, finance	127,000
2024, operating
2024, finance	35,000
2025, operating
2025, finance	3,000
Total lease payments, operating	55,000
Total lease payments, finance	350,000
Less: Imputed interest, finance	(39,000)
Lease liabilities, finance	$ 311,000

Note 7 - Intangible Assets - _3

Note 7 - Intangible Assets - Amortizable (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Amortization of Intangible Assets, Total	$ 1,584,580	$ 953,450	$ 3,169,161	$ 1,528,567
Minimum [Member]
Finite-Lived Intangible Asset, Period before Next Renewal or Extension (Year)			1 year
Maximum [Member]
Finite-Lived Intangible Asset, Period before Next Renewal or Extension (Year)			20 years

Note 7 - Intangible Assets - _4

Note 7 - Intangible Assets - Amortizable - Summary of Intangible Assets (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
Intangible assets, gross carrying amount	$ 58,093,000	$ 58,473,000
Intangible assets, accumulated amortization	(12,394,000)	(9,423,000)
Intangible assets, net carrying amount	$ 45,699,000	$ 48,855,000
Intangible assets, weighted-average remaining life (Year)	9 years 160 days	9 years 40 days
MiOXSYS Patent		$ (195,000)
Licensed Assets [Member]
Intangible assets, gross carrying amount	$ 23,649,000	23,649,000
Intangible assets, accumulated amortization	(8,200,000)	(7,062,000)
Intangible assets, net carrying amount	$ 15,449,281	$ 16,586,847
Intangible assets, weighted-average remaining life (Year)	11 years 262 days	11 years 321 days
Technology-Based Intangible Assets [Member]
Intangible assets, gross carrying amount	$ 22,700,000	$ 22,700,000
Intangible assets, accumulated amortization	(2,648,000)	(1,513,000)
Intangible assets, net carrying amount	$ 20,051,666	$ 21,186,666
Intangible assets, weighted-average remaining life (Year)	8 years 306 days	9 years 124 days
MiOXSYS Patent [Member]
Intangible assets, gross carrying amount		$ 380,000
Intangible assets, accumulated amortization		(185,000)
Intangible assets, net carrying amount
Intangible assets, weighted-average remaining life (Year)
MiOXSYS Patent		$ (195,000)
Distribution Rights [Member]
Intangible assets, gross carrying amount	$ 11,354,000	11,354,000
Intangible assets, accumulated amortization	(1,319,000)	(565,000)
Intangible assets, net carrying amount	$ 10,035,000	$ 10,789,000
Intangible assets, weighted-average remaining life (Year)	7 years 98 days	7 years 284 days
Customer Lists [Member]
Intangible assets, gross carrying amount	$ 390,000	$ 390,000
Intangible assets, accumulated amortization	(227,000)	(98,000)
Intangible assets, net carrying amount	$ 163,000	$ 292,000
Intangible assets, weighted-average remaining life (Year)	226 days	1 year 43 days

Note 7 - Intangible Assets - _5

Note 7 - Intangible Assets - Amortizable - Estimated Future Amortization Expense (Details) - USD ($)	Dec. 31, 2020	Jun. 30, 2020
2021	$ 3,157,000
2022	6,085,000
2023	6,045,000
2024	6,033,000
2025	4,480,000
Thereafter	19,899,000
Finite-Lived Intangible Assets, Net, Ending Balance	$ 45,699,000	$ 48,855,000

Note 8 - Accrued Liabilities -

Note 8 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($)		Dec. 31, 2020	Dec. 30, 2020	Jun. 30, 2020
Accrued settlement expense			$ 150,000	$ 315,000
Accrued program liabilities			1,386,000	959,000
Accrued product-related fees			2,332,000	2,471,000
Credit card liabilities			712,000	510,000
Medicaid liabilities			2,094,000	1,842,000
Return reserve			1,656,000	1,329,000
Sales taxes payable			175,000	175,000
Other accrued liabilities*	[1]		373,000	249,000
Total accrued liabilities		$ 8,877,715	$ 8,878,000	$ 7,849,855
[1]	Other accrued liabilities consist of franchise tax, accounting fee, interest payable, merchant services charges, none of which individually represent greater than five percent of total current liabilities.

Note 9 - Fair Value Considera_3

Note 9 - Fair Value Considerations (Details Textual) shares in Thousands	Mar. 31, 2020USD ($)shares	Feb. 14, 2020USD ($)shares	Nov. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jun. 30, 2020USD ($)	Nov. 02, 2018USD ($)	Jun. 11, 2018USD ($)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				$ 3,313,656		$ 2,411,333
Gain (Loss) from Change in Fair Value of CVR						(899,987)
Tuzistra XR [Member]
Business Combination, Contingent Consideration, Liability, Total				15,800,000		15,800,000			$ 8,800,000
Tuzistra XR [Member] | Forecast [Member]
Payment for Contingent Consideration Liability, Operating Activities			$ 3,000,000
ZolpiMist [Member]
Business Combination, Contingent Consideration, Liability, Total				300,000		300,000				$ 2,600,000
Innovus Pharmaceuticals [Member]
Business Combination, Contingent Consideration, Liability, Total		$ 200,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				15,000	15,000	28,000	28,000
Business Combination, Contingent Value Rights, Maximum Range of Outcomes		$ 16,000,000
Business Combination, Maximum Shares to be Issued to Settle CVR (in shares) | shares		470
Stock Issued During Period, Shares, Contingent Value Rights (in shares) | shares	120
Stock Issued During Period, Value, Contingent Value Rights	$ 2,000,000
Business Combination, Contingent Value Rights, First Revenue Milestone	24,000,000
Gain (Loss) from Change in Fair Value of CVR	$ 300,000			$ (100,000)	$ (100,000)	$ (800,000)	$ (800,000)	$ 300,000
Innovus Pharmaceuticals [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input		0.3

Note 9 - Fair Value Considera_4

Note 9 - Fair Value Considerations - Financial Liabilities Accounted for at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	Dec. 31, 2020	Jun. 30, 2020
Contingent consideration	$ 16,280,000	$ 13,588,000
CVR liability	6,472,000	5,572,000
Financial and Nonfinancial Liabilities, Fair Value Disclosure	22,752,000	19,160,000
Fair Value, Inputs, Level 1 [Member]
Contingent consideration		13,588,000
CVR liability		5,572,000
Financial and Nonfinancial Liabilities, Fair Value Disclosure		$ 19,160,000
Fair Value, Inputs, Level 2 [Member]
Contingent consideration
CVR liability
Financial and Nonfinancial Liabilities, Fair Value Disclosure
Fair Value, Inputs, Level 3 [Member]
Contingent consideration	16,280,000
CVR liability	6,472,000
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 22,752,000

Note 9 - Fair Value Considera_5

Note 9 - Fair Value Considerations - Summary of Level 3 Input Changes (Details)	6 Months Ended
	Dec. 31, 2020USD ($)
CVR Liability [Member]
Balance	$ 5,572,000
Transfers into Level 3
Transfer out of Level 3
Included in earnings	900,000
Included in other comprehensive income
Purchases
Issues
Sales
Settlements
Balance	6,472,000
Contingent Consideration [Member]
Balance	13,588,000
Transfers into Level 3
Transfer out of Level 3
Included in earnings	2,735,000
Included in other comprehensive income
Purchases
Issues
Sales
Settlements	(43,000)
Balance	$ 16,280,000

Note 9 - Fair Value Considera_6

Note 9 - Fair Value Considerations - Significant Assumptions (Details)	Dec. 31, 2020
Credit Risk Assumption [Member]
Contingent consideration, measurement input	0.191
Contingent value rights, measurement input	0.096
Time Steps Per Year [Member]
Contingent consideration, measurement input	1
Contingent value rights, measurement input	30
Sales Volatility [Member]
Contingent consideration, measurement input	0.45
Number of Iterations [Member]
Contingent consideration, measurement input	500
Contingent value rights, measurement input	10,000
Credit Spread [Member]
Contingent consideration, measurement input	0.04

Note 10 - Commitments and Con_3

Note 10 - Commitments and Contingencies (Details Textual) shares in Thousands	May 29, 2020USD ($)	Mar. 31, 2020USD ($)shares	Nov. 01, 2019USD ($)	Jan. 31, 2020USD ($)	May 31, 2016USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019	Jun. 30, 2018	May 01, 2020USD ($)	Feb. 14, 2020USD ($)	Feb. 28, 2015USD ($)
Gain (Loss) from Change in Fair Value of CVR								$ (899,987)
Contractual Obligation, Total						$ 38,320,000		38,320,000
Tris Pharma, Inc. [Member] | Karbinal Agreement [Member]
Supply and Distribution Commitment, Period (Year)			20 years
Supply and Distribution Commitment, Total Royalty, Percentage of Net Sales			23.50%
Supply and Distribution Commitment, Third Party, Royalty, Percentage of Net Sales			8.50%
Supply and Distribution Commitment, Royalty, Percentage of Net Sales											15.00%	15.00%
Supply and Distribution Agreement, Maximum Yearly Make-whole Payment			$ 2,100,000
Supply and Distribution Agreement, Minimum Sales Per Year			70,000
Supply and Distribution Agreement, Make-whole Payment Per Unit for Sales Under Minimum			$ 30
Supply and Distribution Agreement, Maximum Milestone Obligations			3,000,000
Supply and Distribution Agreement, First Milestone, Minimum Net Revenues			40,000,000
Innovus Pharmaceuticals [Member]
Stock Issued During Period, Shares, Contingent Value Rights (in shares) | shares		120
Stock Issued During Period, Value, Contingent Value Rights		$ 2,000,000
Business Combination, Contingent Value Rights, First Revenue Milestone		24,000,000
Gain (Loss) from Change in Fair Value of CVR		$ 300,000				(100,000)	$ (100,000)	(800,000)	$ (800,000)	$ 300,000
Business Combination, Contingent Consideration, Liability, Total														$ 200,000
Novalere [Member] | Innovus Pharmaceuticals [Member]
Business Acquisition, Contingent Consideration, Number of Payments															5
Business Acquisition, Contingent Consideration, Payment Upon Each Sales Milestone															$ 500,000
Business Combination, Contingent Consideration, Liability, Total						200,000		200,000
Prescription Database [Member]
Unrecorded Unconditional Purchase Obligation, Total					$ 1,600,000
Unrecorded Unconditional Purchase Obligation, Term (Year)					3 years
Contractual Obligation, Total						1,278,000		1,278,000
Prescription Database [Member] | The Pediatric Portfolio [Member]
Unrecorded Unconditional Purchase Obligation, Total				$ 600,000
First Pediatric Portfolio Fixed Obligation [Member]
Contractual Obligation, Monthly Payment			86,840
Contractual Obligation, Balloon Payment			15,000,000
Repayments of Fixed Obligation	$ 15,000,000
Second Pediatric Portfolio Fixed Obligation [Member]
Contractual Obligation, Monthly Payment			$ 100,000
Payments for Fixed Obligations to Investor				$ 210,767
Inventories [Member]
Contractual Obligation, Total						1,717,000		1,717,000
Inventories [Member] | Hikma Pharmaceuticals USA, Inc. [Member]
Unrecorded Unconditional Purchase Obligation, Total													$ 1,000,000
Product Milestone Payments [Member]
Contractual Obligation, Total						$ 3,000,000		$ 3,000,000

Note 10 - Commitments and Con_4

Note 10 - Commitments and Contingencies - Summary of Commitments and Contingencies (Details)	Dec. 31, 2020USD ($)
Total	$ 38,320,000
2021	5,176,000
2022	9,769,000
2023	8,300,000
2024	8,300,000
2025	3,300,000
Thereafter	3,475,000
Prescription Database [Member]
Total	1,278,000
2021	545,000
2022	733,000
2023
2024
2025
Thereafter
Pediatric Portfolio Fixed Payments and Product Minimums [Member]
Total	15,825,000
2021	1,650,000
2022	3,300,000
2023	3,300,000
2024	3,300,000
2025	3,300,000
Thereafter	975,000
Inventories [Member]
Total	1,717,000
2021	981,000
2022	736,000
2023
2024
2025
Thereafter
CVR Liability [Member]
Total	14,000,000
2021	2,000,000
2022	2,000,000
2023	5,000,000
2024	5,000,000
2025
Thereafter
Product Contingent Liability [Member]
Total	2,500,000
2021
2022
2023
2024
2025
Thereafter	2,500,000
Product Milestone Payments [Member]
Total	3,000,000
2021
2022	3,000,000
2023
2024
2025
Thereafter

Note 11 - Capital Structure (De

Note 11 - Capital Structure (Details Textual) - USD ($)	Dec. 10, 2020	Jul. 31, 2020	Jun. 30, 2020	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Common Stock, Shares Authorized (in shares)			200,000,000	200,000,000		200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001	$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized (in shares)			50,000,000	50,000,000		50,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001	$ 0.0001		$ 0.0001
Common Stock, Shares, Outstanding, Ending Balance (in shares)			12,583,736	17,882,893		17,882,893
Preferred Stock, Shares Outstanding, Ending Balance (in shares)			0	0		0
Stock Issued During Period, Value, New Issues				$ 28,317,444
Payments of Stock Issuance Costs						$ 4,292,781	$ 741,650
Class of Warrant or Right, Issued During Period (in shares)						403,760
Wainwright [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares)	4,791,667
Underwriting Agreement, Commitment Offering, Shares (in shares)	4,166,667
Shares Issued, Price Per Share (in dollars per share)	$ 6
Underwriting Agreement, Overallotment Option, Shares (in shares)	625,000
Conversion of Debt to Common Stock [Member]
Debt Conversion, Original Debt, Amount	$ 800,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)	130,081
Warrants Issued in Connection with March Offerings [Member]
Class of Warrant or Right, Issued During Period (in shares)		92,302
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		92,302
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)		$ 15.99
Warrants and Rights Outstanding, Term (Year)		1 year
Warrants and Rights Outstanding		$ 356,000
Warrants Issued in Connection With Wainwright Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)	311,458
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	311,458
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 7.50
At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)			430,230	352,912	0
Stock Issued During Period, Value, New Issues			$ 6,800,000	$ 3,600,000
Payments of Stock Issuance Costs			$ 200,000	$ 100,000
The March Offerings [Member]
Payments of Stock Issuance Costs		$ 1,500,000
Restricted Stock [Member]
Common Stock, Shares, Outstanding, Ending Balance (in shares)				365,869		365,869

Note 12 - Equity Incentive Pl_3

Note 12 - Equity Incentive Plan (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Feb. 13, 2020	Jul. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	0	0	0	0
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 494,000		$ 494,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years 248 days
The 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					5,000,000	3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	4,560,864		4,560,864
The 2015 Plan [Member] | Restricted Stock [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			6 years 109 days
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 4,300,000		$ 4,300,000
Non-plan [Member] | Restricted Stock [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			5 years 182 days
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 1,100,000		$ 1,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)	158		158

Note 12 - Equity Incentive Pl_4

Note 12 - Equity Incentive Plan - Stock Option Activity (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020
Outstanding, number of options (in shares)			76,614
Outstanding, weighted average exercise price (in dollars per share)			$ 19.39
Outstanding, weighted average remaining contractual life (Year)			9 years 29 days		9 years 244 days
Granted, number of options (in shares)	0	0	0	0
Granted, weighted average exercise price (in dollars per share)
Exercised, number of options (in shares)
Exercised, weighted average exercise price (in dollars per share)
Forfeited/Cancelled, number of options (in shares)			(3,187)
Forfeited/Cancelled, weighted average exercise price (in dollars per share)
Expired, number of options (in shares)			(2)
Expired, weighted average exercise price (in dollars per share)
Outstanding, number of options (in shares)	73,425		73,425		76,614
Outstanding, weighted average exercise price (in dollars per share)	$ 19.71		$ 19.71		$ 19.39
Outstanding, aggregate intrinsic value
Exercisable at December 31, 2020 (in shares)	9,095		9,095
Exercisable at December 31, 2020 (in dollars per share)	$ 67.62		$ 67.62
Exercisable at December 31, 2020 (Year)			7 years 295 days
Exercisable at December 31, 2020

Note 12 - Equity Incentive Pl_5

Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details) - Restricted Stock [Member] - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
Unvested at June 30, 2020 (in shares)	418,454
Unvested at June 30, 2020 (in dollars per share)	$ 14.69
Unvested at June 30, 2020 (Year)	6 years 109 days	6 years 146 days
Vested, number of shares (in shares)	(52,743)
Unvested at December 31, 2020 (in shares)	365,711	418,454
Unvested at December 31, 2020 (in dollars per share)	$ 15.66	$ 14.69

Note 12 - Equity Incentive Pl_6

Note 12 - Equity Incentive Plan - Stock-based Compensation Expense (Details) - Selling, General and Administrative Expenses [Member] - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Total stock-based compensation expense	$ 508,000	$ 162,000	$ 963,000	$ 327,000
Share-based Payment Arrangement, Option [Member]
Total stock-based compensation expense	94,000	2,000	166,000	7,000
Restricted Stock [Member]
Total stock-based compensation expense	$ 414,000	$ 160,000	$ 797,000	$ 320,000

Note 13 - Warrants (Details Tex

Note 13 - Warrants (Details Textual) - USD ($)	Dec. 15, 2020	Jul. 31, 2020	Dec. 31, 2020
Class of Warrant or Right, Issued During Period (in shares)			403,760
Warrants Issued in Connection with March Offerings [Member]
Class of Warrant or Right, Issued During Period (in shares)		92,302
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)		$ 15.99
Warrants and Rights Outstanding, Term (Year)		1 year
Warrants and Rights Outstanding		$ 356,000
December 15, 2020 Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)	311,458
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)	$ 7.50
Warrants and Rights Outstanding	$ 1,300,000

Note 13 - Warrants - Significan

Note 13 - Warrants - Significant Assumptions in Valuing Warrants Issued (Details)	Dec. 31, 2020
Measurement Input, Option Volatility [Member]
Warrants, assumptions	1
Measurement Input, Expected Term [Member]
Warrants, assumptions	5
Measurement Input, Risk Free Interest Rate [Member]
Warrants, assumptions	0.37
Measurement Input, Expected Dividend Rate [Member]
Warrants, assumptions	0

Note 13 - Warrants - Summary of

Note 13 - Warrants - Summary of Equity-based Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
Outstanding, number of warrants (in shares)	2,288,528
Outstanding, weighted average remaining contractual life (Year)	1 year 237 days	2 years
Warrants issued, number of warrants (in shares)	403,760
Warrants expired, number of warrants (in shares)	(842)
Warrants exercised, number of warrants (in shares)
Outstanding, number of warrants (in shares)	2,691,446	2,288,528
Weighted Average [Member]
Outstanding, weighted average exercise price (in dollars per share)	$ 30.26
Outstanding, weighted average exercise price (in dollars per share)	$ 26.94	$ 30.26

Note 14 - Net Loss Per Common_3

Note 14 - Net Loss Per Common Share - Antidilutive Securities Excluded from Calculation of Diluted Earnings Per Share (Details) - shares	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive securities (in shares)	3,154,845	2,195,528
Liability Warrants [Member]
Antidilutive securities (in shares)	24,105	24,105
Equity-based Warrants [Member]
Antidilutive securities (in shares)	2,691,446	1,621,891
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	73,425	156
Restricted Stock [Member]
Antidilutive securities (in shares)	365,869	234,261
Convertible Preferred Stock [Member]
Antidilutive securities (in shares)		315,115

Note 15 - Notes Payable (Detail

Note 15 - Notes Payable (Details Textual) - USD ($)	Dec. 10, 2020	Nov. 01, 2020	Jan. 09, 2020	Feb. 27, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Gain (Loss) on Exchange of Debt					$ (257,559)		$ (257,559)
Conversion of Debt to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	130,081
Gain (Loss) on Exchange of Debt	$ 300,000
Debt Conversion, Original Debt, Amount	$ 800,000
Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount				$ 800,000
Proceeds from Notes Payable, Total				$ 600,000
Debt Instrument, Term (Month)		240 days
Debt Instrument, Unamortized Discount (Premium), Net, Total		$ 200,000
Amortization of Debt Discount (Premium)					15,000	$ 0	70,000	$ 0
Notes Payable, Other Payables [Member] | Innovus Pharmaceuticals [Member]
Debt Instrument, Face Amount			$ 500,000
Proceeds from Notes Payable, Total			$ 400,000
Debt Instrument, Term (Month)			1 year
Debt Instrument, Periodic Payment, Total			$ 45,000
Notes Payable, Total					$ 41,000		$ 41,000

Note 16 - Segment Reporting (De

Note 16 - Segment Reporting (Details Textual)	6 Months Ended
	Dec. 31, 2020
Number of Reportable Segments	2

Note 16 - Segment Reporting - S

Note 16 - Segment Reporting - Select Financial Information for Segments (Details) - USD ($)	3 Months Ended				6 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020
Consolidated revenue	$ 15,147,000		$ 3,175,000		$ 29,000,000	$ 4,615,000
Consolidated net loss	(9,525,294)	$ (4,305,931)	(214,247)	$ (4,929,030)	(13,831,224)	(5,143,277)
Total assets	166,742,096				166,742,096		$ 152,836,330
Aytu Bioscience [Member]
Consolidated revenue	7,212,000		3,175,000		13,000,000	4,615,000
Consolidated net loss	(8,267,000)		(214,000)		(11,218,000)	(5,143,000)
Total assets	140,647,000				140,647,000		126,267,000
Aytu Consumer Health [Member]
Consolidated revenue	7,935,000				16,000,000
Consolidated net loss	(1,258,000)				(2,613,000)
Total assets	$ 26,095,000				$ 26,095,000		$ 26,569,000

Note 17 - Related Party Trans_2

Note 17 - Related Party Transactions (Details Textual) - Tris Pharma, Inc. [Member] - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Oct. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Tris License Agreement [Member]
Related Party Transaction, Amounts of Transaction		$ 1.9	$ 0.2
Due to Related Parties, Total		$ 24.1	$ 24.8
Karbinal Fixed Payment Obligation [Member]
Related Party Transaction, Amounts of Transaction	$ 1.6